【国药现代：阿奇霉素干混悬剂通过仿制药一致性评价】国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。

金融界2025-06-26

国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2546782511?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-26 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546782511","market":"us","top_or_hot":-1,"title":"【国药现代：阿奇霉素干混悬剂通过仿制药一致性评价】国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。","media":"金融界","content":"<div>\n<p>国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/06/26190851327499.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【国药现代：阿奇霉素干混悬剂通过仿制药一致性评价】国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【国药现代：阿奇霉素干混悬剂通过仿制药一致性评价】国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-26 19:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/06/26190851327499.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/06/26190851327499.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/06/26190851327499.shtml","article_id":"2546782511","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546782511","pubTimestamp":1750936139,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600420":"国药现代","01093":"石药集团","BK1515":"抗疫概念","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","02348":"东瑞制药","BK1574":"生物医药B类股","BK0010":"央企","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","BK0020":"浦东新区","BK0239":"医药制造","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","01558":"东阳光长江药业","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01477":"欧康维视生物-B","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK0082":"国资改革","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","BK0132":"高送转概念","BK1191":"制药","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC"},"translate_title":"[Sinopharm Modern: Azithromycin dry suspension passed the consistency evaluation of generic drugs] Sinopharm Modern announced that the company's azithromycin dry suspension passed the consistency evaluation of generic drug quality and efficacy. The sales of azithromycin dry suspension in public medical institutions and urban pharmacies nationwide in 2024 will be 1.475 billion yuan. At present, the enterprises that have passed the consistency evaluation include CSPC Ouyi Pharmaceutical Co., Ltd., Yichang Dongyang Yangtze River Pharmaceutical Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., H","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600420":1,"01093":1,"01558":1,"02348":1,"01477":1},"content_text":"国药现代公告，公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售，但业绩影响存在不确定性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546782511","isCrawlerRequest":true}